Omar Alhalabi

Omar Alhalabi is an Assistant Professor at The University of Texas MD Anderson Cancer Center, specializing in genitourinary oncology. His research focuses on bladder cancer, germ cell tumors, and renal cell carcinoma, with particular emphasis on immunotherapy resistance, antibody-drug conjugates, and targeted therapies. His recent work includes investigating TROP-2 targeted therapy in bladder carcinomas with APC mutations, analyzing outcomes of enfortumab vedotin and pembrolizumab combinations in advanced urothelial carcinoma, and exploring circulating tumor DNA as a real-time biomarker in marker-negative germ cell tumors. He has published extensively in the Journal of Clinical Oncology and leads multi-institutional studies on somatic transformations and histologic dedifferentiation in metastatic clear cell renal cell carcinoma.